RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Keros Therapeutics P/E 2024

Keros Therapeutics P/E

-7.72

Keros Therapeutics Dividend yield

Ticker

KROS

ISIN

US4923271013

WKN

A2P2YF

As of Jun 1, 2024, Keros Therapeutics's P/E ratio was -7.72, a -16.09% change from the -9.2 P/E ratio recorded in the previous year.

The Keros Therapeutics P/E history

Keros Therapeutics Aktienanalyse

What does Keros Therapeutics do?

Keros Therapeutics Inc is a biopharmaceutical company that was founded in 2015 by five biotechnology industry experts. The company is based in Lexington, Massachusetts. Keros is an emerging company that focuses on developing innovative therapies for severe diseases resulting from genetic defects. The business model of Keros Therapeutics Inc is to expand its pipeline of innovative therapies through the research, development, and commercialization of drugs that have highly specific mechanisms of action. Keros' business model aims to develop new and differentiated therapies that focus on modulating biological signals and pathways to improve the treatment of serious diseases. Keros Therapeutics Inc has several divisions that focus on different areas of biotechnology. One division of Keros specializes in the development of RNA-modulating therapies for diseases with genetic defects. These therapies target the modulation of RNA splicing processes to influence the causal factor of severe diseases. Another division of Keros focuses on the development of drugs that target the Wnt signaling pathway, a complex protein signaling network that plays an important role in many processes in the body. These Wnt-related drugs target various disease areas such as cancer and fibrosis to improve the treatment of these conditions. The company is currently in the clinical phase and has brought several products to market in various stages of research. One of Keros' key drug candidates is KER-012, a medication for the treatment of Alpha-1 antitrypsin deficiency, a rare and severe disease that often leads to lung and liver conditions. KER-012 aims to develop more effective treatment options for patients by specifically influencing an RNA splicing mechanism in the cells that is associated with the disease. Another drug candidate from Keros is KER-047, a medication for the treatment of Neurofibromatosis type 1, a rare condition that causes tumors in the nervous system. It targets the Wnt signaling pathway to restore control over tumor proliferation and enlargement. Keros has also established partnerships with other biotechnology companies and academic institutions to expand its research and development capabilities and diversify its pipeline. One notable agreement is the collaboration with Arbutus Biopharma to develop RNA modulators for cardiovascular diseases. Overall, Keros Therapeutics Inc aims to develop innovative and effective therapies for a variety of diseases by focusing on biology and signaling pathways that are responsible for disease progression. With a solid therapy pipeline and an experienced group of biotechnology experts, Keros could soon become a leading company in the biopharmaceutical industry. Keros Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Keros Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Keros Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Keros Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Keros Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Keros Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Keros Therapeutics Stock

What is the price-to-earnings ratio of Keros Therapeutics?

The price-earnings ratio of Keros Therapeutics is currently -7.72.

How has the price-earnings ratio of Keros Therapeutics changed compared to last year?

The price-to-earnings ratio of Keros Therapeutics has increased by -16.09% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Keros Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Keros Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Keros Therapeutics affect the company?

An increase in the price-earnings ratio of Keros Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Keros Therapeutics affect the company?

A decrease in the price-earnings ratio of Keros Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Keros Therapeutics?

Some factors that influence the price-earnings ratio of Keros Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Keros Therapeutics pay?

Over the past 12 months, Keros Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Keros Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Keros Therapeutics?

The current dividend yield of Keros Therapeutics is .

When does Keros Therapeutics pay dividends?

Keros Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Keros Therapeutics?

Keros Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Keros Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Keros Therapeutics located?

Keros Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Keros Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Keros Therapeutics from 6/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/1/2024.

When did Keros Therapeutics pay the last dividend?

The last dividend was paid out on 6/1/2024.

What was the dividend of Keros Therapeutics in the year 2023?

In the year 2023, Keros Therapeutics distributed 0 USD as dividends.

In which currency does Keros Therapeutics pay out the dividend?

The dividends of Keros Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Keros Therapeutics

Our stock analysis for Keros Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Keros Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.